The companies struck a multi-year strategic collaboration, under which GSK will have access to Helix's GenoSphere cohorts.
Axovia Therapeutics Nabs $1.1M Grant to Advance BBS1 Vision Loss Gene Therapy Toward Clinical Trials
With this new grant, nonprofit A Race Against Blindness has provided a total of $5.1 million to advance AXV-101.
The new Phase III study will test calderasib in a chemo-free regimen for G12C-mutated patients regardless of PD-L1 status.
The collaboration will support development of Ascidian's RNA exon editor therapy, ACDN-01, for treating the rare genetic eye disease.
The deal brings Dark Blue's preclinical oncology products, including an MLLT1/3-targeted agent for leukemias, into Amgen's portfolio.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback